StreetInsider.com News Articles

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that access to Labcorp’s NASHnext®, a diagnostic test to identify at-risk MASH (Metabolic dysfunction-Associated SteatoHepatitis), powered by GENFIT’s proprietary non-invasive diagnostic technology NIS4®, is

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Mon, 08 Jun 2026 12:00:00 -0400

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH
This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
- Cash and cash equivalents totaled €101.1 million as of December 31, 2025
- Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
- Cash runway beyond the end of 2028
2026 business and pipeline outlook:
- PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
- MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
- CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
- ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Thu, 02 Apr 2026 12:30:00 -0400

2025 financial highlights:
Cash and cash equivalents totaled €101.1 million as of December 31, 2025
Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen
Cash runway beyond the end of 2028

2026 business and pipeline outlook:
PBC: Royalty stream expected to increase, building on Ipsen’s strong 2025 performance
MASH diagnostics: Sales acceleration expected with LDT, initiation of IVD development
CCA: Additional Phase 1 cohort data expected mid‑year, Phase 2 initiation targeted in 2H26
ACLF: Phase 2 initiation with